Retinal Biologics Market Set to Surge to $24.7 Billion by 2032 at a 5.1% CAGR

As of 2022, the retinal biologics market was valued at $14.9 billion and is projected to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032. The global retinal biologics market is experiencing significant growth, driven by advancements in biotechnology and an increasing prevalence of retinal diseases. Retinal biologics are specialized therapeutic agents derived from living organisms, such as proteins or antibodies, designed to target specific molecules or processes involved in retinal disorders. These biologics offer targeted therapies that address the underlying mechanisms of retinal diseases, providing more effective treatment options compared to traditional approaches.

Read More Here: https://www.alliedmarketresearch.com/retinal-biologics-market-A10946

Retinal Biologics Market Growth Factors

Several factors contribute to the growth of the retinal biologics market:

1. Increasing Prevalence of Retinal Diseases: There is a notable rise in the number of individuals suffering from retinal disorders such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, dry AMD accounts for 85% to 90% of AMD cases as of 2021.

2. Aging Population: The global increase in the geriatric population, who are more susceptible to retinal diseases, has led to a higher demand for retinal biologic drugs. According to the World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, further contributing to market growth.

3. Advancements in Biotechnology: Progress in genetic engineering and molecular biology has opened new avenues for developing retinal biologic drugs. Techniques such as gene therapy, cell-based therapies, and RNA interference have shown promise in preclinical and clinical studies, driving research and development activities in this field.

4. Increased Awareness and Early Diagnosis: Organizations like the Foundation Fighting Blindness and the American Macular Degeneration Foundation (AMDF) play crucial roles in promoting awareness, supporting research, and providing resources to patients and their families. These efforts contribute to increased public awareness, leading to early diagnosis and intervention, which in turn drives the demand for retinal biologics.

Get Sample PDF Copy: https://www.alliedmarketresearch.com/request-sample/A10946

Retinal Biologics Market Segmentation

The retinal biologics market is segmented based on drug class, indication, and distribution channel.

1. By Drug Class:
- VEGF-A Antagonists: This segment includes drugs like Aflibercept and Ranibizumab. VEGF-A antagonists are highly effective in treating various retinal diseases, particularly AMD, diabetic retinopathy, and retinal vein occlusion. The high adoption of these drugs is due to their proven efficacy and extensive clinical evidence supporting their use.

- Others: This category encompasses other biologic agents used in retinal disease treatment, including emerging therapies targeting different molecular pathways.

2. By Indication:
- Macular Degeneration: This segment accounted for the largest share in 2022. The high prevalence of age-related macular degeneration, growing awareness about early diagnosis, and advancements in treatment options have increased the demand for biologic drugs for this condition.

- Diabetic Retinopathy: This segment is anticipated to witness the highest growth, owing to the surge in cases of diabetic retinopathy due to sedentary lifestyles, unhealthy diets, and the aging population. The increasing demand for effective treatments for diabetic retinopathy drives this segment's growth.

- Others: This includes other retinal disorders that are treated with biologic agents.

3. By Distribution Channel:
- Hospital Pharmacies: This segment occupied the largest share in 2022, owing to the increase in sales of prescription AMD drugs from hospital pharmacies, collaborative efforts with healthcare providers, and convenient medication delivery services.

- Drug Stores and Retail Pharmacies: These outlets provide accessibility to retinal biologic medications for patients with prescriptions.

- Online Providers: The rise of e-commerce has led to an increase in online pharmacies offering retinal biologics, providing convenience for patients.

Key Players in the Retinal Biologics Market

The retinal biologics market features several key players who contribute to its growth through research, development, and distribution of innovative therapies. Notable companies in this market include:

- Janssen Pharmaceuticals (Johnson & Johnson)
- F. Hoffmann-La Roche Ltd.
- Oxurion NV
- Novartis AG
- Allergan
- MeiraGTx Limited
- Regeneron Pharmaceuticals Inc.
- OncoGene Pharmaceuticals
- AbbVie Inc.

These companies are actively involved in developing and commercializing biologic drugs for retinal diseases, contributing to the market's expansion.

The retinal biologics market is poised for substantial growth, driven by the increasing prevalence of retinal diseases, an aging global population, advancements in biotechnology, and heightened awareness leading to early diagnosis and treatment. As research and development efforts continue, and as key players introduce innovative therapies, the market is expected to expand, offering improved treatment options for individuals affected by retinal disorders.

Procure Complete Report: https://www.alliedmarketresearch.com/checkout-final/0b5999384283d1de5327de5397dd1f24?utm_source=Nilesh.Musale

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.